02/11/2020
Logo of Marie Skłodowska-Curie Actions

InPharma Open PhD Positions – Initial Call, A fully integrated, animal-free, end-to-end modelling approach to oral drug product development, Marie Sklodowska-Curie Actions (MSCA), Innovative Training Networks (ITN)


  • ORGANISATION/COMPANY
    University College Cork
  • RESEARCH FIELD
    Biological sciences
    Chemistry › Physical chemistry
    Engineering › Chemical engineering
    Mathematics
    Pharmacological sciences › Pharmacy
  • RESEARCHER PROFILE
    First Stage Researcher (R1)
  • APPLICATION DEADLINE
    15/01/2021 17:00 – Europe/London
  • LOCATION
    Multiple locations, see work locations below.
  • TYPE OF CONTRACT
    Temporary
  • EU RESEARCH FRAMEWORK PROGRAMME
    H2020 / Marie Skłodowska-Curie Actions
  • MARIE CURIE GRANT AGREEMENT NUMBER
    955756

OFFER DESCRIPTION

InPharma is a MSCA European Industrial Doctorate programme offering a comprehensive training program addressing the challenges of developing emerging drug candidates into new licensed medicines, including innovative modeling and bio-predictive tools tailored to streamline the oral drug product development process.

InPharma brings together global pharmaceutical companies and leading research institutions together as a multi-sectorial team to deliver a unique research and training programme for 13 Early Stage Researchers (ESR) to complete their industrially based PhDs.

Each ESR position in InPharma allows the researcher to work towards a PhD at one of our five leading academic institutions. The ESRs will be recruited within 2021 for a duration of 36 months. Every ESR will work on an independent research project which will be flexible enough to match the competence and goals of the candidate.

Each ESR position in InPharma allows the researcher to work towards a PhD at one of our five leading academic institutions. The ESRs will be recruited within 2021 for a duration of 36 months. Every ESR will work on an independent research project which will be flexible enough to match the competence and goals of the candidate.

Marie Sklodowska-Curie ESRs are paid an attractive gross salary of 3,270 €/month for 36 months (as defined in MSCA guidelines). The exact (net) salary will be confirmed upon appointment and is dependent on local tax, social and health insurance regulations and on the country correction factor (to allow for the difference in cost of living in the different EU Member States). Each ESR will also be compensated with a Mobility Allowance of 600 €/month, and, for researchers who have a family, a Family Allowance of 500 €/month. All amounts are subject to deductions and taxes. Family is defined as persons linked to the researcher by (i) marriage, or (ii) a relationship with equivalent status to a marriage recognised by the national legislation of the country of the beneficiary or of the nationality of the researcher, or (iii) dependent children who are actually being maintained by the researcher; family status is determined at recruitment and does not evolve.

Available positions

ESR1: Optimising drug co-crystal formulation using in vitro dissolution/permeation models

Host: Solvias (Switzerland) & SDU (Denmark)

PhD awarding institution: SDU

Scientific objectives: :1) Assess the relationship between APIs and potential partners in generating co-crystals 2) Develop computational models to predict solvation and intermolecular interaction between drug and co-crystal partners. 3) Assess performance of co-crystals using novel dissolution and permeation models. Industrial: Develop a high throughput screening (HTS) tool to rank co-crystal formulation approaches in early stage drug development.

Additional Requirements: M.Sc. (or equivalent graduation) in relevant area (e.g. Physical Chemistry, Pharmacy, Pharmaceutical Sciences, Drug Delivery or Industrial Pharmacy). Practical hands-on experience with small scale preparation and characterization of solid states and cocrystals is a prerequisite, and additional hands-on experience with advanced in vitro biopharmaceutical methods like dissolution/permeation studies is desired. Proof of English proficiency as communication and teaching language throughout InPharma is English (e.g. TOEFL or similar test, not for native speakers).

Planned secondment:

HostSDU, Denmark; Duration: TBD; Purpose: Dissolution/permeation of co-crystals, PhD courses.

Contact: Dr. Rolf Hilfiker, rolf.hilfiker@solvias.com

ESR2: Modelling drug-excipient solubilisation interactions to predict excipient selection

Host: Roche (Switzerland) & UCC (Ireland)

PhD awarding institution: UCC

Scientific objectives: 1) Explore drug-excipient interactions in both nano-carrier and micellar systems using computational pharmaceutics. 2) Apply QSPR, AI, and ML to predict drug-excipient interactions for nano-carrier and micellar systems. 3) Develop computational tools to guide excipient selection for optimal solubilisation and industrial scalability.

Additional Requirements: M.Sc. (or equivalent graduation) in relevant area (e.g. Pharmacy, Pharmaceutical Sciences, Drug Delivery or Industrial Pharmacy). Proof of English proficiency as communication and teaching language throughout InPharma is English (e.g. TOEFL or similar test, not for native speakers).

Planned secondment:

HostUCC, Ireland; Duration: ~12 months; Purpose: Modelling and data analysis, PhD courses

Contact: Dr. Nicole Wyttenbach, nicole.wyttenbach@roche.com

ESR3: Computational tools to predict co-grinding approaches to overcome dissolution rate limited absorption

Host: Zentiva (Czech Republic)

PhD awarding institution: UCC

Scientific objectives: 1) Evaluate the potential of co-grinding with excipients (e.g. surfactants, cyclodextrins) to enhance the dissolution rate from solid dosage forms. 2) Characterize prototype formulations using advanced methods (e.g., IR, Raman imaging) and model dissolution rate enhancement as a function of drug and excipient properties. 3) Predict in vivo impact of enhanced dissolution rate by integrating newly generated in vitro data in existing PBPK models.

Additional Requirements: M.Sc. (or equivalent graduation) in relevant area (e.g. Pharmacy, Pharmaceutical Sciences, Drug Delivery or Industrial Pharmacy). Proof of English proficiency as communication and teaching language throughout InPharma is English (e.g. TOEFL or similar test, not for native speakers).

Planned secondments:

Host: FHNW, Switzerland; Duration: ~6 months; Purpose: Advanced characterisation methods;

Host: UCC, Ireland; Duration: ~10 months; Purpose: Modelling and data analysis, PhD courses.

Contact: Dr. Josef Benarek, josef.beranek@zentiva.com

ESR4: Molecular dynamics simulations to predict drug supersaturation in microemulsion formulations

Host: UCC (Ireland)

PhD awarding institution: UCC

Scientific objectives: 1) Use molecular dynamics (MD) simulations as an approach to model microemulsion droplet structure and solubilisation capacity for drugs. 2) Employ multivariate analysis to develop models that predict extent of supersaturation (Dosup) in microemulsions using large drug datasets. 3) Develop computational tools to support a rational and science-based approach to selecting microemulsion formulations for new drug candidates.

Additional Requirements: M.Sc. (or equivalent graduation) in relevant area (e.g. Pharmacy, Pharmaceutical Sciences, Drug Delivery or Industrial Pharmacy). Proof of English proficiency as communication and teaching language throughout InPharma is English (e.g. TOEFL or similar test, not for native speakers).

Planned secondment:

Host: Janssen, Belgium; Duration: ~18 months; Purpose: Data generation and MD simulations.

Contact: Dr. Brendan Griffin, brendan.griffin@ucc.ie

ESR5: Novel therapeutic deep eutectic systems (THEDES)

Host: FHNW (Switzerland)

PhD awarding institution: University of Basel

Scientific objectives: New ways are pursued to find and effectively harness so-called novel Therapeutic Deep Eutectic Systems (THEDES). The research work includes the application of computational tools (thermodynamic and molecular modelling) and also much experimental work is planned from compounding to characterisation of mixtures and final dosage forms. Innovation is not only targeted in approaches of finding promising THEDES but there should be also new scientific insights gained into these pertinent new drug delivery systems. Moreover, the industrial environment will guide the research to propose viable results with industrial relevance.

Additional Requirements: M.Sc. (or equivalent graduation) in relevant area (e.g. Pharmacy, Pharmaceutical Sciences or also Chemists and Chemical Engineers)). Proof of English proficiency as communication and teaching language throughout InPharma is English (e.g. TOEFL or similar test, not for native speakers).

Planned secondment:

Host: Zentiva, Czech Republic; Duration: ~18 months; Purpose: Industrial feasibility of novel THEDES.

Contact: Prof. Martin Kuentz, martin.kuentz@fhnw.ch

ESR6: Machine learning using supersaturating drug delivery systems

Host: FHNW (Switzerland)

PhD awarding institution: University of Basel.

Scientific objectives: Several drug delivery technologies are based on the principle of creating drug supersaturation to overcome the hurdle of poor aqueous solubility. This project is primarily on a preformulation level of drugs and their interactions with excipients. Experimental work is planned on mostly high-throughput equipment which enables application of modern approaches of machine learning. Selected mixtures of interest will be also studied by further computational (e.g. molecular modelling) and analytical approaches to elucidate not only innovative drug-excipient mixtures but to provide also a good basis of scientific understanding of drug supersaturation.

Additional Requirements: M.Sc. (or equivalent graduation) in relevant area (e.g. Pharmacy, Pharmaceutical Sciences, or also Chemists and Chemical Engineers). Proof of English proficiency as communication and teaching language throughout InPharma is English (e.g. TOEFL or similar test, not for native speakers).

Planned secondment:

Host: Janssen, Belgium; Duration: ~18 months; Purpose: Experimental data collection;

Host: Hafnium, Denmark; Duration: ~2 months; Purpose: Training and modelling using Q-props® tools

Contact: Prof. Martin Kuentz, martin.kuentz@fhnw.ch

ESR7: Comparison of rDCS (refined Development Classification System) to the pre-clinical suspension/solution approach for formulation selection

Host: Janssen (Belgium) & Fraunhofer (Germany)

PhD awarding institution: Fraunhofer

Scientific objectives: 1) Utilize primary human cells for determination of permeability for rDCS purposes 2) Apply the rDCS approach to inform formulation selection for a range of drug candidates. 3) Advance the framework of customised investigations for DCS Class IIb/IV drugs. Industrial Compare rDCS-based approach to animal-based formulation selection approaches (using literature and in-house industrial data)

Additional Requirements: M.Sc. (or equivalent) in a relevant area (Pharmacy, Pharmaceutical Sciences, Drug Delivery or Industrial Pharmacy). Proof of English proficiency (e.g. TOEFL or similar test, exemption for native speakers), since communication internally and externally in this project will be English.

Planned secondment:

Host: Fraunhofer; Duration: ~18 months; Purpose: Permeability studies & ‘Customized’ rDCS tests.

Contact: Dr. René Holm, rholm@its.jnj.com

ESR8: Predicting the dissolution gains and precipitation risks of salt and co-crystal forms of drugs

Host: Astra Zeneca (Sweden)

PhD awarding institution: Johann Wolfgang Goethe University (Germany)

Scientific objectives: 1) Develop a biorelevant in vitro model of salt / co-crystal dissolution and precipitation for simulated human GI tract and validate/refine PBBM model using the data; (2) Validate reliability of PBBM model by comparing to in-house in vivo data. Industrial: Develop a dynamic in vitro dissolution approach to screen salts / co-crystals and an in-silico model predicting performance in the human GI tract.

Additional Requirements: M.Sc. (or equivalent graduation) in relevant area (e.g. Pharmacy, Pharmaceutical Sciences, Drug Delivery or Industrial Pharmacy). Proof of English proficiency as communication and teaching language throughout InPharma is English (e.g. TOEFL or similar test, not for native speakers). Although not a requirement, experience of PBBM modelling and a physical chemistry background is desirable.

Planned secondment:

Host: JWGU; Duration: ~6 months; Purpose: Transfer model testing and PBPK modelling, PhD courses.

Contacts: Dr Sara Carlert, Advanced Drug Delivery, Dr. Eva Karlsson, Sara.Carlert@astrazeneca.comEva.M.Karlsson@astrazeneca.com

ESR9: Development of an in vitro method for evaluating the impact of gastrointestinal (GI) transfer on performance of enabling formulations under fed state conditions

Host: National and Kapodistrian University of Athens (NKUA, Greece)

PhD awarding institution: NKUA

Objectives: Scientific: 1) Conduct a clinical study to assess the GI transfer process of amorphous solid dispersions in the fed state; 2) Design biorelevant in vitro testing conditions for evaluating the drug disposition in the upper GI lumen after oral administration of immediate release/enabling products in the fed state. Industrial: Develop and assess the utility of in vitro models to reproduce intraluminal drug data, after administration of immediate release/enabling products in the fed state.

Requirements: M.Sc. (or equivalent graduation) in relevant area (e.g. Pharmacy, Pharmaceutical Sciences, Drug Delivery or Industrial Pharmacy). Proof of English proficiency as communication and teaching language throughout InPharma is English (e.g. TOEFL or similar test, not for native speakers).

Planned secondment:

Host: Janssen, Belgium; Duration: ~18 months

Contact: Prof. Christos Reppas, reppas@pharm.uoa.gr

ESR10: In silico methods for selecting oral formulations and dosing conditions in early clinical studies

Host: Bayer (Germany)

PhD awarding institution: NKUA

Objectives: Scientific: 1) Development of PBPK models for oral drug formulations using in vitro to in vivo extrapolation techniques; 2) Evaluate the extrapolation results using clinical data after administration of immediate release/enabling drug products. Industrial: Evaluation of PBPK models for early formulation benchmarking and dose selection to be administered in early clinical studies.

Additional Requirements: M.Sc. (or equivalent graduation) in relevant area (e.g. pharmacy/pharmaceutical sciences, natural sciences, medicine, engineering, and/or mathematics). Proof of English proficiency as communication and teaching language throughout InPharma is English (e.g. TOEFL or similar test, not for native speakers). Experience with mechanistic modelling and parameter estimation in ODE systems would be an advantage.

Planned secondment:

Host: NKUA, Greece; Duration: ~6 months;

Contact: Dr. André Dallmann, andre.dallmann@bayer.com

ESR11: Integrating in vitro dissolution-permeation data with biopharmaceutical models to predict the in vivo performance of drug formulations

Host: University of Southern Denmark

PhD awarding institution: SDU

Objectives: Scientific: 1) Benchmark a range of dissolution/permeation methods and develop integrated PBPK models with increasing levels of complexity using enabling formulations e.g. solubilised systems, nano-carriers, THEDES, or co-grinding with surfactant/cyclodextrin products; (2) Verify predictability of PBPK models by comparison with human reference data. Industrial: Develop a new guide on optimal selection of in vitro dissolution-permeation methods and in silico tools during formulation development for poorly soluble drugs.

Additional Requirements: M.Sc. (or equivalent graduation) in relevant area (e.g. Pharmacy, Pharmaceutical Sciences, Drug Delivery or Industrial Pharmacy). Substantial hands-on experience with explorative dissolution models, preferably combined dissolution/permeation studies of enabling formulations is a prerequisite; experience with PBPK modelling and IVIVC studies is an advantage. Proof of English proficiency as communication and teaching language throughout InPharma is English (e.g. TOEFL or similar test, not for native speakers).

Planned secondments:

Host: Roche, Switzerland; Duration: ~18 months; Purpose: Formulation manufacturing; in vitro characterization; in silico modelling;

Host: NKUA, Greece; Duration: ~2 months; Purpose: Evaluation of alternative in vitro model (BioGIT)

Contact:  Prof. Annette Bauer-Brandl,  annette.bauer@sdu.dk

ESR12: Application of an end–to-end, animal-free modelling approach to the development of enabling drug products: focus on amorphous solid dispersions (ASD)

Host: Fraunhofer (Germany)

PhD awarding institution: Fraunhofer

Objectives: Scientific: 1) Apply the refined Development Classification System (rDCS) to assess suitability of various drugs for formulation as an ASD. 2) Develop computational pharmaceutics approach for ASD formulation design. 3) Couple Biorelevant in vitro testing with PBPK modelling to simulate bioavailability advantages of ASDs. Industrial: Compare the end-to-end modelling approach to current screening practices at Roche for formulations and applied to emerging drugs of interest to Roche.

Additional Requirements: M.Sc. (or equivalent graduation) in relevant area (e.g. Pharmacy, Pharmaceutical Sciences, Drug Delivery or Industrial Pharmacy). Proof of English proficiency as communication and teaching language throughout InPharma is English (e.g. TOEFL or similar test, not for native speakers).

Planned secondments:

Host: Roche, Switzerland; Duration: ~18 months; Purpose: Comparison of end-to-end approach versus current industrial workflow.

Host: Certara, United Kingdom; Duration: ~5 months; Purpose: PBPK modelling using the SimCYP Simulator®

Contact: Prof. Dr. Jennifer Dressman, jennifer.dressman@ime.fraunhofer.de

ESR13: Developing a novel two-stage in vitro lipolysis model to predict impact of digestion on drug absorption from supersaturating formulations

Host: Janssen (Belgium) & SDU

PhD awarding institution: SDU .

Objectives:Scientific: 1) Develop a high throughput in vitro digestion/permeation method by incorporating a lipolysis step; 2) Assess impact of digestion on supersaturating formulations/excipient effects on permeation. Industrial: Benchmark the new method to the current industrial approaches e.g. single-stage pH-stat lipolysis method in terms of reliability, scalability and robust-ness

Additional Requirements: M.Sc. (or equivalent graduation) in relevant area (e.g. Pharmacy, Pharmaceutical Sciences, Drug Delivery or Industrial Pharmacy). Proof of English proficiency as communication and teaching language throughout InPharma is English (e.g. TOEFL or similar test, not for native speakers).

Planned secondments:

Host: SDU, Denmark; Duration: TBD;

Contact: Dr. René Holm,  rholm@its.jnj.com

For more details on these positions see: https://www.inpharma-network.eu/open-positions/.

Map Information

 Job Work Location
WORK LOCATION(S)
1 position(s) availabl a
University College Cork
Ireland
Cork
1 position(s) available at
University of Southern Denmark
Denmark
Odense
2 position(s) available at
University of Basel
Switzerland
Basel
1 position(s) available at
Frauenhofer
Germany
Frankfurt am Main
1 position(s) available at
National and Kapodistrian University of Athens
Greece
Athens
1 position(s) available at
Solvias AG
Switzerland
Kaiseraugst
1 position(s) available at
Zentiva K.S.
Czech Republic
Prague
2 position(s) available at
Janssen Pharmaceautica NV
Belgium
Geel
1 position(s) available at
AstraZeneca AB
Sweden
Mölndal
1 position(s) available at
Bayer AG
Germany
Leverkusen

Open, Transparent, Merit based Recruitment procedures of Researchers (OTM-R)

Know more about it at University College Cork

Know more about OTM-R

EURAXESS offer ID: 573453

Disclaimer:

The responsibility for the jobs published on this website, including the job description, lies entirely with the publishing institutions. The application is handled uniquely by the employer, who is also fully responsible for the recruitment and selection processes.

Please contact support@euraxess.org if you wish to download all jobs in XML.